HomeCompareEMAN vs MRK

EMAN vs MRK: Dividend Comparison 2026

EMAN yields 96.62% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMAN wins by $3.33M in total portfolio value
10 years
EMAN
EMAN
● Live price
96.62%
Share price
$2.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.39M
Annual income
$1,116,384.81
Full EMAN calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — EMAN vs MRK

📍 EMAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMANMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMAN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMAN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMAN
Annual income on $10K today (after 15% tax)
$8,212.56/yr
After 10yr DRIP, annual income (after tax)
$948,927.09/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, EMAN beats the other by $940,330.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMAN + MRK for your $10,000?

EMAN: 50%MRK: 50%
100% MRK50/50100% EMAN
Portfolio after 10yr
$1.72M
Annual income
$563,249.30/yr
Blended yield
32.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EMAN
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-3.6
Piotroski
1/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMAN buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMANMRK
Forward yield96.62%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3.39M$57.7K
Annual income after 10y$1,116,384.81$10,113.78
Total dividends collected$3.01M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: EMAN vs MRK ($10,000, DRIP)

YearEMAN PortfolioEMAN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$20,362$9,661.84$11,213$373.04+$9.1KEMAN
2$40,173$18,386.23$12,667$512.06+$27.5KEMAN
3$76,888$33,902.42$14,439$708.14+$62.4KEMAN
4$142,911$60,641.04$16,640$988.16+$126.3KEMAN
5$258,254$105,339.35$19,432$1,394.07+$238.8KEMAN
6$454,237$177,905.06$23,057$1,992.90+$431.2KEMAN
7$778,476$292,441.92$27,889$2,894.79+$750.6KEMAN
8$1,301,370$468,401.47$34,518$4,286.29+$1.27MEMAN
9$2,124,263$731,796.56$43,912$6,494.35+$2.08MEMAN
10$3,389,346$1,116,384.81$57,714$10,113.78+$3.33MEMAN

EMAN vs MRK: Complete Analysis 2026

EMANStock

eMagin Corporation engages in the design, develop, manufacture, and market of organic light-emitting diode (OLED) miniature displays on-silicon micro displays, virtual imaging products that utilize OLED micro displays, and related products in the United States and internationally. It offers super video graphics array (SVGA) + OLED micro displays; digital SVGA OLED-XL; super extended graphics array OLED-XL/XLS; video graphics array OLED-XL; and widescreen ultra-extended graphics array OLED-XL. The company also provides design reference kits, which include a micro display and associated electronics to help original equipment manufacturers (OEMs) to evaluate micro display products; near-eye virtual imaging modules that incorporate its OLED-on-silicon micro displays with its lenses and electronic interfaces for integration into OEM products; prism optics, a molded plastic prism lens that permits its AMOLED micro displays to provide realistic images that can be viewed for extended periods with reduced eye-fatigue; and driver boards. Its products are used in military aviation helmets, military weapons sights and targeting systems, night vision and thermal imaging devices, training and simulation, visualization for ocular surgery, mobile ultrasound, and augmented reality applications. The company was founded in 1996 and is headquartered in Hopewell Junction, New York.

Full EMAN Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EMAN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMAN vs SCHDEMAN vs JEPIEMAN vs OEMAN vs KOEMAN vs MAINEMAN vs JNJEMAN vs ABBVEMAN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.